Epilepsy, Seizures, and Medical Cannabis: Recent PubMed Findings

What the Latest Peer‑Reviewed Research Says

The studies below were selected from PubMed, the U.S. National Library of Medicine’s database of peer‑reviewed articles. They provide a snapshot of current scientific inquiry into epilepsy, seizures, and the potential role of medical cannabis. This overview is for educational purposes only and does not constitute medical advice. If you have questions about treatment options, please talk to a licensed physician.

1. Cannabidiol and Cognitive Health in Cancer Survivors

A 2024 study published in Cancer Letters investigated whether cannabidiol (CBD) could reduce cognitive decline caused by chemotherapy. The researchers followed breast cancer patients who received standard chemotherapy drugs doxorubicin and cyclophosphamide. They measured signs of neuroinflammation and neurodegeneration as markers of cognitive impairment. The study reported that patients who received CBD showed reduced levels of these markers compared with those who did not receive CBD. The authors noted that these findings suggest a possible protective effect of CBD against chemotherapy‑related cognitive changes, though they called for larger, controlled trials to confirm the results.

Source: PubMed entry

2. How Neurologists Manage Uncontrolled Epilepsy in Spain

A 2024 survey in Neurology and Therapy collected opinions from Spanish neurologists about treating patients whose seizures remain uncontrolled after standard medication. The 23‑question online survey asked about clinicians’ familiarity with antiseizure medications, their use of adjunctive therapies, and their attitudes toward newer options, including cannabis. The results showed that while most neurologists had experience with conventional drugs, a smaller proportion reported routinely considering medical cannabis as part of their treatment repertoire. The authors highlighted a need for clearer guidelines and more research to guide clinicians in this area.

Source: PubMed entry

3. Cannabidiol in Pediatric Epilepsy: A One‑Year Observation

In a 2024 prospective study published in Epilepsy & Behavior, 103 children with drug‑resistant epilepsy in Australia were followed for one year while receiving purified CBD through a compassionate access program. Clinicians recorded seizure frequency, quality of life, and any adverse events. The study found that a notable proportion of participants experienced a reduction in seizure frequency, and most reported no serious side effects. However, the authors emphasized that the open‑label design limits definitive conclusions and that controlled studies are needed to clarify efficacy and safety.

Source: PubMed entry

4. Precision Medicine for Potassium‑Channel Epilepsies

A systematic review in Current Neuropharmacology (2024) examined research on potassium‑channel gene variants linked to epilepsy. The review screened over 2,200 papers and identified 60 that met strict inclusion criteria. The authors summarized how specific genetic mutations affect neuronal excitability and discussed emerging therapies that target these channels. While the review did not focus on cannabis, it highlighted the importance of individualized treatment plans and suggested that future studies could explore how cannabinoids interact with specific genetic profiles.

Source: PubMed entry

5. FDA Approval of Epidiolex and Lennox‑Gastaut Syndrome Diagnoses

After the FDA approved Epidiolex, a pharmaceutical‑grade CBD product, for Lennox‑Gastaut syndrome (LGS) in 2018, researchers examined whether this approval influenced diagnostic practices. A 2023 study in Epileptic Disorders used a large electronic health record database to track new LGS diagnoses from 2017 to 2023. The analysis revealed a temporary increase in reported LGS cases shortly after approval, followed by a return to baseline levels. The authors suggested that heightened awareness and increased testing may have contributed to the initial spike, but the long‑term impact on diagnosis remains unclear.

Source: PubMed entry

6. CBD in CDKL5 Deficiency Disorder

CDKL5 deficiency disorder (CDD) is a rare, early‑onset epileptic encephalopathy. A 2023 open‑label prospective study in Epilepsia Open investigated the effects of highly purified CBD on seizure frequency and other symptoms in individuals with CDD. The researchers followed participants over several months, recording seizures, sleep patterns, and motor function. Preliminary results indicated a trend toward reduced seizure frequency and improved sleep in some patients, though the study size was limited and the authors called for randomized controlled trials to confirm these observations.

Source: PubMed entry

Key Takeaways for Patients

• Current research suggests that CBD may influence neuroinflammation and seizure frequency in certain populations, but evidence is still preliminary.
• Neurologist surveys indicate that medical cannabis is not yet a standard option in many clinical settings, and more education is needed.
• Precision medicine approaches, especially for genetic forms of epilepsy, are growing; future studies may clarify how cannabinoids fit into these personalized plans.
• Changes in diagnosis rates following regulatory approvals highlight how policy can affect clinical practice, though the long‑term effects on patient outcomes are not yet fully understood.

What This Means for You

Science about medical cannabis and epilepsy is evolving. While some studies show promise, none provide definitive proof of effectiveness or safety. If you are considering medical cannabis as part of your epilepsy management, discuss it with a qualified healthcare provider who can help evaluate risks, benefits, and potential interactions with your current medications.

For more information about medical cannabis options in Florida, or to learn how Compassionate Alternative Care can help you navigate the process, visit our website or contact us directly.